$36.7 Billion Worldwide Diabetes Devices Industry to 2027

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

September 16, 2020

“Diabetes Devices – Global Market Trajectory & Analytics”: Research and Markets bring years of research experience to the 6th edition of this report. The 180-page report presents concise insights into how the pandemic has impacted production and the buy-side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Diabetes Devices Market to Reach $36.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Diabetes Devices estimated at US$24.7 Billion in the year 2020, is projected to reach a revised size of US$36.7 Billion by 2027, growing at a CAGR of 5.8% over the period 2020-2027.

Monitoring and Diagnostic Devices, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$26.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Insulin Delivery Devices segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 8.9% CAGR

The Diabetes Devices market in the U.S. is estimated at US$6.7 Billion in the year 2020. China, the world`s second-largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Competitors identified in this market include, among others:

  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Medtronic PLC
  • Novo Nordisk A/S
  • Sanofi SA

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares
  • Diabetes Devices Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

Additional information can be found here.

spot_img

DON'T MISS

Related Articles